.. Aeterna Zentaris presents outcomes of orally active substances with anti-tumor effects at EORTC-NCI-AACR Symposium Aeterna Zentaris Inc. Data implies that AEZS-129 and AEZS-132 block essential signalling pathways which contribute to the proliferation and survival of cancer cells. Targeting these multiple signalling pathways could result in improved treatment efficacy for such cancers as lung, colon, prostate, breasts, endometrial melanoma and cancer. Both posters were offered by Irene Seipelt, Associate Director, Preclinical and Discovery Advancement at Aeterna Zentaris, during the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Tumor Therapeutics currently held at the Berlin Estrel Resort and Convention Center in Berlin, Germany. Juergen Engel, Ph.D., President and CEO of Aeterna Zentaris stated, Data from the studies on AEZS-129 and AEZS-132 presented today, demonstrate that these two novel orally energetic anti-cancer substances can inhibit the development of tumor cells without vital safety issues.The researchers developed a real way to trigger disease fighting capability antibodies to fight an array of flu subtypes. They said the approach proved effective in tests on monkeys and rodents. In the lab animals, this approach created antibodies against H5N1 bird flu even, the study noted. The findings were published online Aug. 24 in the journal Science. The scholarly study was funded by Janssen Pharmaceuticals. Researchers from Janssen are working with researchers from The Scripps Research Institute in La Jolla, Calif., to develop the vaccine. ‘This study implies that we’re moving in the right direction for a general flu vaccine,’ Ian Wilson, professor of structural biology and chair of the division of integrative structural and computational biology at The Scripps Study Institute, said in an institute news release.